Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: A multicentric phase II study

Cancer

Volumn 97, Issue 11, 2003, Pages 2791-2797

  Favaretto, Adolfo G ^a   Aversa, Savina M L ^a   Paccagnella, Adriano ^b   Manzini, Vincenzo De Pangher ^c   Palmisano, Valentina ^d   Oniga, Francesco ^b   Stefani, Micaela ^a   Rea, Federico ^a   Bortolotti, Luigi ^a   Loreggian, Lucio ^a   Monfardini, Silvio ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b Civic Hospital   (Italy)

^c Monfalcone Hospital   (Italy)

^d Vittorio Veneto Hospital   (Italy)

Author keywords

Carboplatin; Clinical benefit; Gemcitabine; Multicentric trial; Phase II study; Pleural mesothelioma

Indexed keywords

CARBOPLATIN; GEMCITABINE;

ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DISEASE COURSE; DOSE RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; SURVIVAL RATE;

EID: 0037844997     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11405     Document Type: Article

References (34)

1. Connelly RR, Spirtas R, Myers MH, et al. Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst. 1987;78:1053-1060.
2. Zanetti R, Gafà L, Pannelli F, Conti E, Rosso S. Cancer in Italy. Incidence data from cancer registries 1993-1998. Volume 3. Rome: I? pensiero Scientifico Editore, 2002.
3. Carbone M, Pass HI, Rizzo P, et al. Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene. 1994;9:1781-1790.
4. Procopio A, Strizzi L, Vianale G, et al. Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. Genes Chromosomes Cancer. 2000;29:173-179.
5. Vogelzang NJ, Rusthoven J, Paoletti P, et al. Phase III single-blinded study of pemetrexed plus cisplatin vs cisplatin alone in chemonaive patients with malignant pleural mesothelioma [abstract]. Proc Am Soc Clin Oncol. 2002;21:2a.
6. Baas P, Schouwink H, Zoetmulder FAN. Malignant pleural mesothelioma. Ann Oncol. 1998;9:139-149.
7. Mbidde EK, Smith IE, Harland SJ. Phase II trial of carboplatin in the treatment of patients with malignant pleural mesothelioma. Br J Cancer. 1986;54:215-216.
8. Rusch VW for the International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest. 1995;108:1122-1128.
9. Paladine W, Cunningham TJ, Sponzo R, et al. Intracavitary bleomycin in the management of malignant effusions. Cancer. 1976;38:1903-1908.
10. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. WHO recommendations for grading of acute and subacute toxicity. Cancer. 1981;47:207-214.
11. Simon R. Optimal two-stage design for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
12. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-481.
13. Pollock RE, Karnell LH, Menck HR, Winchester DP. The national cancer data base report on soft tissue sarcoma. Cancer. 1996;78:2247-2257.
14. Chahinian AP, Antman K, Goutsou M, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol. 1993;11:1559-1565.
15. Ruffie P, Minkin FS, Cormier Y, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol. 1989;7:1157-1168.
16. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding along procedure tracts in pleural mesothelioma: a randomized trial of local radiotherapy. Chest. 1995;108:754-758.
17. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol. 1996;14:1007-1017.
18. Raghavan D, Gianoutsos P, Bishop J. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol. 1990;8:151-154.
19. Vogelzang NJ, Goutsou M, Corson JM. Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol. 1990;27: 239-242.
20. Nowak A, Byrne M, Williamson R, et al. Multicentre phase II study of cisplatin and gemcitabine in malignant mesothelioma[abstract]. Ann Oncol. 2000;11(Suppl 4):109.
21. Byrne M, Davidson J, Musk A, et al. Cisplatin and gemcitabine for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17:25-30.
22. Van Haarst J, Burgers J, Manegold C, et al. Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma [abstract]. Lung Cancer. 2000;29 (Suppl 1): 18.
23. Van Meerbeeck JP, Baas P, Debruyne C, et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer. 1999;85:2577-2582.
24. Kindler H, Millard F, Herndon J. Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2001;31:311-317.
25. Bischoff HG, Manegold C, Knopp M, et al. Gemcitabine may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma [abstract]. Proc Am Soc Clin Oncol. 1998;17:464.
26. Steele J, Shamash J, Evans M, et al. Phase II trial of vinorelbine and oxaliplatin in malignant pleural mesothelioma [abstract]. Proc Am Soc Clin Oncol. 2001;20:335a.
27. Fizazi K, Caliandro R, Soulie P, et al. Combination raltitrexed-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Eur J Cancer. 2000;36:1514-1521.
28. Nakano T, Chahinian P, Shinjo M, et al. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma. A pilot phase II clinical trial and pharmacokinetic profile. Cancer. 1999;85:2375-2384.
29. Soto Parra H, Tixi L, Latteri F, et al. Combined regimen of cisplatin, doxorubicin and α-2b interferon in the treatment of advanced malignant pleural mesothelioma. Cancer. 2001;92:650-656.
30. Pinto C, Marino A, Guaraldi M, et al. Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma. Am J Clin Oncol. 2001;24:143-147.
31. Berghmans T, Paesmans M, Lalami Y, et al. Chemotherapy for malignant pleural mesothelioma: a quantitative and qualitative overview of the literature [abstract]. Proc Am Soc Clin Oncol. 1999;18:481.
32. Soto Parra H, Cavina R, Latteri F, et al. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol. 2002;13:1080-1086.
33. Hughes A, Calvert P, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol. 2002;20:3533-3544.
34. Sugarbaker DJ, Flores R, Jacklitsch M, et al. Resection margins, extrapleural nodal status, and cell type determine post-operative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54-65.